Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.77 EUR | +0.27% | +1.07% | +19.30% |
May. 23 | FAES FARMA : Faes Farma is now receiving the long-awaited attention from investors | |
Apr. 26 | FAES FARMA : Q1 beat; full-year guidance re-affirmed |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is in a robust financial situation considering its net cash and margin position.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- Most analysts recommend that the stock should be sold or reduced.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+19.30% | 1.27B | B | ||
+43.64% | 749B | C+ | ||
+39.42% | 605B | B | ||
-6.58% | 351B | C+ | ||
+19.72% | 328B | B- | ||
+8.78% | 292B | C+ | ||
+11.92% | 216B | B- | ||
-2.62% | 214B | A+ | ||
+0.03% | 167B | C+ | ||
+6.13% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FAE Stock
- Ratings Faes Farma, S.A.